Qnovia, Inc. announces FDA clearance of IND application for lead asset RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy ...Middle East

- Phase 1 clinical trial for smoking cessation expected to dose first patient in 4Q 2024 - - The study will evaluate the pharmacokinetics, safety and tolerability of the RespiRx™ Nicotine Inhaler compared to Nicotrol® Inhaler and combustible cigarettes - RICHMOND, Va., Oct. 1, 2024...

Hence then, the article about qnovia inc announces fda clearance of ind application for lead asset respirx nicotine inhaler as a prescription smoking cessation therapy was published today ( Tuesday 01/10/2024 - 02:40 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Qnovia, Inc. announces FDA clearance of IND application for lead asset RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy )

Also on site :

• Small Modular Reactors Are the Perfect Fit for Kazakhstan’s Power Grid
• China Passes Amendments to Foreign Trade Law to Boost Trade War Capabilities
• Why China Is Driving Short-Term Oil Prices But OPEC Still Holds the Lever